Melanoma in situ

CD2_INSITU_MELANOMA

melanoma: A malignant, usually aggressive tumor composed of atypical, neoplastic melanocytes. Most often, melanomas arise in the skin (cutaneous melanomas) and include the following histologic subtypes: superficial spreading melanoma, nodular melanoma, acral lentiginous melanoma, and lentigo maligna melanoma. Cutaneous melanomas may arise from acquired or congenital melanocytic or dysplastic nevi. Melanomas may also arise in other anatomic sites including the gastrointestinal system, eye, urinary tract, and reproductive system. Melanomas frequently metastasize to lymph nodes, liver, lungs, and brain.

Endpoint definition

FinnGen phenotype data

356077 individuals

diagram downward connector

Apply sex-specific rule None

356077

diagram downward connector

Check conditions None

356077

diagram downward connector
diagram bullet

Filter registries

Hospital Discharge: ICD-10 D03
Cause of death: ICD-10 D03

-

diagram downward connector
diagram bullet

Check pre-conditions, main-only, mode, ICD version

Look only at ICD versions H.D: 10 ; C.O.D: 10

-

diagram downward connector

Check minimum number of events None

-

diagram downward connector
CD2_INSITU_MELANOMA

Extra metadata

Level in the ICD hierarchy 2
First used in FinnGen datafreeze DF2
Parent code in ICD-10 D00-D09
Name in latin Melanoma in situ

Similar endpoints

Summary Statistics

Key figures

All Female Male
Number of individuals 798 390 408
Unadjusted prevalence (%) 0.22 0.20 0.26
Mean age at first event (years) 66.79 63.58 69.85

Mortality

Follow-up Absolute risk HR [95% CI] p N
1998–2019 0.03 1.70 [0.86, 3.37] 1.3e-1 61
15 years 0.01 0.86 [0.41, 1.79] 6.9e-1 30
5 years 0.00 1.30 [0.68, 2.49] 4.3e-1 20
1 year 0.00 3.41 [1.62, 7.17] 1.2e-3 10

Age distribution of first events

Year distribution of first events

Cumulative Incidence

Correlations

Index endpoint: CD2_INSITU_MELANOMA – Melanoma in situ
GWS hits:

Survival analyses between endpoints

Plot

before Melanoma in situ
after Melanoma in situ

loading spinner Loading survival analyses plot

Drugs most likely to be purchased after Melanoma in situ